Hong, J.-B.; Wu, P.-Y.; Qin, A.; Huang, Y.-W.; Tseng, K.-C.; Lai, C.-Y.; Chan, W.-K.; Fang, J.; Cutler, D.L.; Tsai, T.-F.
Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results. Pharmaceutics 2022, 14, 2159.
https://doi.org/10.3390/pharmaceutics14102159
AMA Style
Hong J-B, Wu P-Y, Qin A, Huang Y-W, Tseng K-C, Lai C-Y, Chan W-K, Fang J, Cutler DL, Tsai T-F.
Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results. Pharmaceutics. 2022; 14(10):2159.
https://doi.org/10.3390/pharmaceutics14102159
Chicago/Turabian Style
Hong, Jin-Bon, Po-Yuan Wu, Albert Qin, Yi-Wen Huang, Kuan-Chiao Tseng, Ching-Yu Lai, Wing-Kai Chan, Jane Fang, David L. Cutler, and Tsen-Fang Tsai.
2022. "Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results" Pharmaceutics 14, no. 10: 2159.
https://doi.org/10.3390/pharmaceutics14102159
APA Style
Hong, J.-B., Wu, P.-Y., Qin, A., Huang, Y.-W., Tseng, K.-C., Lai, C.-Y., Chan, W.-K., Fang, J., Cutler, D. L., & Tsai, T.-F.
(2022). Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results. Pharmaceutics, 14(10), 2159.
https://doi.org/10.3390/pharmaceutics14102159
